Do serologic markers predict histologic severity or response to treatment in patients with autoimmune hepatitis?
The prevalence of ANAs or ASMAs did not correlate with the clinical or histologic severity of AIH at diagnosis. Furthermore, there was no correlation between antibody status and response to immunosuppressive therapy. Therefore, patients who meet the diagnosis of AIH on the basis of the revised scoring system of International Autoimmune Hepatitis Group should be given immunosuppressive therapy, regardless of antibody status.
CTA, using a 16-channel detector, can be used to accurately screen at-risk patients for BCVI.